[go: up one dir, main page]

AR030310A1 - 2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas - Google Patents

2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas

Info

Publication number
AR030310A1
AR030310A1 ARP010103716A ARP010103716A AR030310A1 AR 030310 A1 AR030310 A1 AR 030310A1 AR P010103716 A ARP010103716 A AR P010103716A AR P010103716 A ARP010103716 A AR P010103716A AR 030310 A1 AR030310 A1 AR 030310A1
Authority
AR
Argentina
Prior art keywords
alkyl
pyrido
pyrimidin
compounds
independently
Prior art date
Application number
ARP010103716A
Other languages
English (en)
Inventor
James Marino Hamby
Sylvester Klutchko
James Bernard Kramer
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR030310A1 publication Critical patent/AR030310A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de 2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas de formula (1), donde R1, R2, R5 y R6 son independientemente H, halogeno, preferiblemente Cl, alquilo de C1-6, alcoxi de C1-6, tio, tialquilo, hidroxi, alcanoilo de C1-6, -CN, -NO2, alcanoiloxi de C1-6, COOR8, -CF3, NR8R9, o (X)m-(CH2)n-NR8R9, donde R8 y R9 son independientemente H, halogeno, alquilo de C1-6, alcanoilo de C1-6, o R8 y R9 junto con el N al cual están unidos pueden completar un anillo de 3 a 7 átomos de C, que puede contener de 1 a 3 heteroátomos como N, N substituido y S, X es NH u O, m es 0 o 1, n es de 0 a 6 siempre que m y n no sean ambos, 0, R3 y R4 son independientemente alquilo de C1-6 o alquilo de C1-6 substituido, R7 es H, alquilo de C1-6, alquenilo de C2-6 o cicloalquilo de C3-6, y sus sales farmacéuticamente aceptables y solvatos. Ejemplos de estos compuestos son 6-(3, 5-dimetoxi-fenil)8-etil-2-(piridin-4-ilamino)-8H-pirido[2, 3-d]pirimidin-7-ona y 6-(3, 5- dimetoxi-fenil)-2-(2-metil-piridin-4-ilamino)-8-etil-8H-pirido[2, 3-d]pirimidin-7-ona. Se usan para preparar una composicion farmacéutica, junto con un portador, excipiente o diluyente, util para el tratamiento de angiogénesis incontrolada, cáncer, ateroesclerosis, artritis reumatoide, restenosis, psoriasis, retinopatía diabética, degeneracion macular y otras enfermedades asociadas con vasos sanguíneos aberrantes y migracion de células endoteliales (EC), regidas por el factor de crecimiento endotelial vascular (VEGF) y el de crecimiento de fibroblastos básicos (VGF). Estos compuestos y composiciones son más potentes, selectivos, biodisponibles y estables que los existentes en el arte previo.
ARP010103716A 2000-08-04 2001-08-03 2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas AR030310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22308300P 2000-08-04 2000-08-04

Publications (1)

Publication Number Publication Date
AR030310A1 true AR030310A1 (es) 2003-08-20

Family

ID=22834955

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103716A AR030310A1 (es) 2000-08-04 2001-08-03 2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas

Country Status (21)

Country Link
US (1) US7022711B2 (es)
EP (1) EP1307450B1 (es)
JP (1) JP2004519422A (es)
AP (1) AP1333A (es)
AR (1) AR030310A1 (es)
AT (1) ATE408613T1 (es)
AU (1) AU2001277032A1 (es)
BR (1) BR0112857A (es)
CA (1) CA2417942C (es)
DE (1) DE60135854D1 (es)
DO (1) DOP2001000227A (es)
ES (1) ES2311532T3 (es)
GT (1) GT200100158A (es)
HN (1) HN2001000171A (es)
MX (1) MXPA02011263A (es)
PA (1) PA8524101A1 (es)
PE (1) PE20020305A1 (es)
SV (1) SV2002000572A (es)
TN (1) TNSN01118A1 (es)
UY (1) UY26867A1 (es)
WO (1) WO2002012238A2 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303385T1 (de) * 2000-08-04 2005-09-15 Warner Lambert Co Verfahren zur herstellung von 2-(4-pyridyl)amino- 6-dialkylolxaphenyl-pyrido(2,3-d)pyrimidon-7-on derivaten
JP2004505974A (ja) * 2000-08-04 2004-02-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルキルオキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン類の製造方法
PL218692B1 (pl) 2002-01-22 2015-01-30 Warner Lambert Co Podstawiony 2-(pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-on oraz jego zastosowanie do leczenia zaburzenia lub stanu spowodowanego nieprawidłową proliferacją komórek
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
EP1527345A2 (en) * 2002-07-29 2005-05-04 Axxima Pharmaceuticals AG Method for isolating atp binding proteins by means of immobilized protein inhibitors
CN100420687C (zh) * 2002-12-20 2008-09-24 霍夫曼-拉罗奇有限公司 作为选择性kdr和fgfr抑制剂的吡啶并[2,3-d]嘧啶衍生物
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2545258A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
JP5520433B2 (ja) 2004-01-21 2014-06-11 エモリー ユニバーシティー 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006038112A1 (en) * 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
EP1942898B2 (en) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
FR2896246B1 (fr) * 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AR062760A1 (es) * 2006-09-13 2008-12-03 Takeda Pharmaceutical Administracion de inhibidores de dipeptidilpetidasa
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
JP2010509265A (ja) * 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
AU2011272198B2 (en) 2010-06-30 2016-09-22 Fujifilm Corporation Novel nicotinamide derivatives or salts thereof
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
RU2679130C2 (ru) * 2012-07-11 2019-02-06 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
EP3060560A1 (en) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2018005865A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
SG11201907909TA (en) * 2017-02-27 2019-09-27 Betta Pharmaceuticals Co Ltd Fgfr inhibitor and application thereof
WO2020041770A1 (en) 2018-08-24 2020-02-27 G1 Therapeutics, Inc. Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
MX2020013757A (es) 2018-09-14 2021-03-02 Abbisko Therapeutics Co Ltd Inhibidor del fgfr, metodo de preparacion y aplicacion del mismo.
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
US20240024216A1 (en) * 2021-01-06 2024-01-25 The Penn State Research Foundation Methods and materials for treating hair loss
US12268677B2 (en) 2022-04-27 2025-04-08 The Penn State Research Foundation 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
JP2004505974A (ja) * 2000-08-04 2004-02-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルキルオキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン類の製造方法
ATE303385T1 (de) * 2000-08-04 2005-09-15 Warner Lambert Co Verfahren zur herstellung von 2-(4-pyridyl)amino- 6-dialkylolxaphenyl-pyrido(2,3-d)pyrimidon-7-on derivaten

Also Published As

Publication number Publication date
TNSN01118A1 (en) 2005-11-10
UY26867A1 (es) 2001-10-25
PA8524101A1 (es) 2002-10-24
ES2311532T3 (es) 2009-02-16
AU2001277032A1 (en) 2002-02-18
WO2002012238A2 (en) 2002-02-14
ATE408613T1 (de) 2008-10-15
DE60135854D1 (de) 2008-10-30
DOP2001000227A (es) 2002-12-15
CA2417942C (en) 2010-06-29
HN2001000171A (es) 2001-09-21
EP1307450B1 (en) 2008-09-17
MXPA02011263A (es) 2003-03-10
GT200100158A (es) 2002-07-18
JP2004519422A (ja) 2004-07-02
EP1307450A2 (en) 2003-05-07
AP2001002230A0 (en) 2001-09-30
WO2002012238A3 (en) 2002-05-10
US20030220345A1 (en) 2003-11-27
US7022711B2 (en) 2006-04-04
SV2002000572A (es) 2002-07-18
BR0112857A (pt) 2005-02-09
AP1333A (en) 2004-11-28
CA2417942A1 (en) 2002-02-14
PE20020305A1 (es) 2002-05-09

Similar Documents

Publication Publication Date Title
AR030310A1 (es) 2-(4-piridil)amino-6-dialcoxifenil-pirido[2,3-d]pirimidin-7-onas
US9938264B2 (en) Proteolysis targeting chimera compounds and methods of preparing and using same
AU2014351571B2 (en) 1 -(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer
JP2025508702A (ja) キナゾリン化合物、及び変異ｋｒａｓタンパク質の阻害剤としてのその使用
JP6318156B2 (ja) キナーゼをモジュレートするための化合物および方法、ならびにその指標
CA2902594C (en) Inhibitors of the kynurenine pathway
CA2874967C (en) Pteridines as fgfr inhibitors
ES2490191T3 (es) Derivados de 2-amino-nicotinamida y su uso como inhibidores de tirosina quinasa del receptor de VEGF
EP2655340B1 (en) Bi-heteroaryl compounds as vps34 inhibitors
AU2011277935B2 (en) Substituted imidazoquinoline derivatives as kinase inhibitors
AU2015302908B2 (en) Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
HRP20171998T1 (hr) Spojevi i sastavi za liječenje parazitnih bolesti
EA025011B1 (ru) ПУРИНЫ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR КИНАЗЫ, ИХ ИСПОЛЬЗОВАНИЕ И ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
AR040971A1 (es) Compuestos pirimido que tienen actividad antiproliferativa
PE20211703A1 (es) Compuesto derivado heterotriciclico novedoso y uso del mismo
AR116880A1 (es) Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano, forma polimórfica del mismo y el uso de los mismos para el tratamiento del hcm
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
KR20150096769A (ko) 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
US20090227575A1 (en) 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
JP2025535046A (ja) Ｋｒａｓ ｇ１２ｃ変異タンパク質の複素環阻害剤及びその使用
NZ629189A (en) Liver x receptor modulators
RU2012128551A (ru) Производные этинила
EP3298001A1 (en) Novel dgat2 inhibitors
RU2018130069A (ru) Соединения и композиции для лечения криптоспоридиоза

Legal Events

Date Code Title Description
FA Abandonment or withdrawal